Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

by NASDAQ Market News October 12, 2020

NASDAQ Market News
Click here to email author

Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies

New Data Demonstrates Economic Benefit of Exagen’s AVISE® Lupus Test for Payors

Ads